FHR MM represents a subset of patients with an aggressive disease course characterized by early relapse (ER), even when treated with novel agents including proteasome inhibitors (PIs) and/or immunomodulatory drugs (IMiDs), autologous stem cell transplantation (ASCT) and CD38 antibody [4, 5, 6]. Here, CD38 is linked to Miyoshi myopathy.